UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 1,517,551 Shares of Pfizer Inc. $PFE

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,713,035 shares of the biopharmaceutical company's stock after acquiring an additional 1,517,551 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.63% of Pfizer worth $889,255,000 at the end of the most recent quarter.Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionOther large investors have also bought and sold shares of the company. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in Pfizer in the 4th quarter valued at $26,000. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter valued at $28,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors. Pfizer News RoundupHere are the key news stories impacting Pfizer this week: Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title Wall Street Analyst Weigh In2 Ways to Play the Big Pharma Patent CliffA number of research analysts have commented on PFE shares. Zacks Research upgraded Pfizer from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 24th. Wolfe Research reissued an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Thursday, April 9th. UBS Group reissued a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $28.82.Read Our Latest Stock Analysis on PfizerPfizer Stock Performance5 High-Yield Stocks to Shield Your Portfolio From the StormShares of Pfizer stock opened at $26.19 on Friday. The company has a market capitalization of $149.26 billion, a PE ratio of 19.99 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock's fifty day simple moving average is $26.43 and its 200 day simple moving average is $26.32. Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm's revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year. Pfizer Announces DividendThe firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer's dividend payout ratio (DPR) is presently 131.30%. Pfizer Company Profile (Free Report)Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas. Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.Featured ArticlesFive stocks we like better than PfizerSpaceX Rings the Bell and Shatters Every RecordAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?3 Dividend Stocks Under $50 That Pay You to Wait Out InflationThe 127-Gigawatt Problem: Why AI Needs Its Own PowerThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Pfizer Right Now?Before you consider Pfizer, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here